Stock ALMDP MEDESIS PHARMA S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Medesis Pharma S.A.

Equities

ALMDP

FR0010844464

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 08:19:25 2024-04-26 am EDT 		5-day change 1st Jan Change
1.4 EUR -2.10% Intraday chart for Medesis Pharma S.A. -10.83% +61.29%
2023 Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
2023 MEDESIS : Invest Securities confirms its recommendation CF

Valuation

Fiscal Period: December 2021 2022
Capitalization 1 22.53 8.675
Enterprise Value (EV) 1 20.92 9.751
P/E ratio -8.52 x -3.16 x
Yield - -
Capitalization / Revenue 235 x 44 x
EV / Revenue 219 x 49.4 x
EV / EBITDA -6.84 x -3.1 x
EV / FCF - -
FCF Yield - -
Price to Book 13.7 x -8.2 x
Nbr of stocks (in thousands) 4,365 4,390
Reference price 2 5.160 1.976
Announcement Date 4/21/22 4/25/23
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022
Net sales 1 0.2085 0.0957 0.1973
EBITDA 1 -0.895 -3.06 -3.142
EBIT 1 -0.9879 -3.215 -3.244
Operating Margin -473.81% -3,358.25% -1,644%
Earnings before Tax (EBT) 1 -0.9905 -3.21 -3.229
Net income 1 -0.7911 -2.647 -2.749
Net margin -379.43% -2,764.69% -1,393.3%
EPS 2 -0.2420 -0.6059 -0.6261
Free Cash Flow - - -
FCF margin - - -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 4/21/22 4/21/22 4/25/23
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022
Net Debt 1 1.22 - 1.08
Net Cash position 1 - 1.61 -
Leverage (Debt/EBITDA) -1.364 x - -0.3424 x
Free Cash Flow - - -
ROE (net income / shareholders' equity) - 1,212% -935%
ROA (Net income/ Total Assets) - -77.8% -65%
Assets 1 - 3.401 4.232
Book Value Per Share 2 -0.6400 0.3800 -0.2400
Cash Flow per Share 2 0.0200 0.0400 0.0600
Capex - - -
Capex / Sales - - -
Announcement Date 4/21/22 4/21/22 4/25/23
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MEDESIS PHARMA S.A. Stock Medesis Pharma S.A.
+61.29% 6.62M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALMDP Stock
  4. Financials Medesis Pharma S.A.